Search
XOMA Royalty Corp
XOMAAdd to Watchlist
43.000USD
+0.380+0.89%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
512.12MMarket Cap
26.03P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+0.89%
5 Days
+2.02%
1 Month
+1.42%
6 Months
+53.63%
Year to Date
+61.71%
1 Year
+59.50%
Key Figures
42.620Open
43.000High
137.66KVolume
26.03P/E TTM
LossP/E Dynamic
2.156Dividend TTM
1.16%Turnover Ratio
42.620Prev. Close
42.460Low
4.37MTurnover
LossP/E Static
5.52P/B
5.01%Div Yield TTM
13.95%ROA
42.81052wk High
0.91Volume Ratio
-19.29MNet Profit
11.91MShares
1.6521EPS TTM
0.89Beta
22.47%ROE
22.29052wk Low
1.27%Amplitude
100.00%Gross Margin
512.12MMarket Cap
0.19Reward/Risk
2.78%Risk Rate
TradingKey Stock Score of XOMA Royalty Corp
Currency: USD Updated: 2026-07-02Key Insights
XOMA Royalty Corp's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 33 out of 83 in the Media & Publishing industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 44.50.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
XOMA Royalty Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
XOMA Royalty Corp Highlights
StrengthsRisks
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 996.03% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 52.15M.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 26.03, at a high 3-year percentile range.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 16.53 shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.27.
Analyst Rating
Based on
3
analysts
Hold
Current Rating
44.500
Target Price
+4.41%
Upside Space
XOMA Royalty Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
XOMA Royalty Corp Info
XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Ticker SymbolXOMA
CompanyXOMA Royalty Corp
CEOMr. Owen P. Hughes, Jr.
Websitehttps://xoma.com/
Related Instruments
+4.07%
+3.92%
+1.05%
+0.85%
+1.26%
-3.25%
+1.80%
-1.23%
+1.91%
+1.11%
-1.27%
+1.38%
-2.19%
+4.65%
+1.57%
+1.61%
-0.19%
+0.93%
+0.12%
+4.34%Popular Instruments
52852.900
+10.400 (+0.02%)
29669.900
+358.500 (+1.22%)
7507.800
+36.300 (+0.49%)
14963.000
+160.000 (+1.08%)
69676.000
+1528.000 (+2.24%)
6412.400
+59.600 (+0.94%)
68.683
+0.339 (+0.50%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4174.610
+52.700 (+1.28%)
FAQs
What is the current price of XOMA Royalty Corp (XOMA)?
The current price of XOMA Royalty Corp (XOMA) is 43.00.
What is the symbol of XOMA Royalty Corp?
The ticker symbol of XOMA Royalty Corp is XOMA.
What is the 52-week high of XOMA Royalty Corp?
The 52-week high of XOMA Royalty Corp is 42.81.
What is the 52-week low of XOMA Royalty Corp?
The 52-week low of XOMA Royalty Corp is 22.29.
What is the market capitalization of XOMA Royalty Corp?
The market capitalization of XOMA Royalty Corp is 512.12M.
Is XOMA Royalty Corp (XOMA) currently rated as Buy, Hold, or Sell?
According to analysts, XOMA Royalty Corp (XOMA) has an overall rating of signal_hold, with a price target of 44.50.
What is the Earnings Per Share (EPS TTM) of XOMA Royalty Corp (XOMA)?
The Earnings Per Share (EPS TTM) of XOMA Royalty Corp (XOMA) is 1.53.